Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company OrthoLogic has initiated dosing for its AZX100 randomized, placebo controlled, dose-escalation, single center Phase I human clinical trial in dermal or hypertrophic scarring.
Subscribe to our email newsletter
In this study safety and tolerability of escalating doses of AZX100 will be evaluated in healthy adult male subjects. A placebo control arm is included in this Phase I study for comparison of injection sites. Approximately 30 adult subjects will be enrolled at an experienced inpatient Phase I study clinic. The primary objective is to evaluate the initial safety and tolerability of AZX100 drug product in healthy adult subjects.
Randolph Steer, president of OrthoLogic, said: “We are pleased that dosing has begun in our AZX100 Phase I human clinical trial program in dermal scarring. The goal of our program for AZX100 is to develop a safe and effective medication for an unmet market need, and it is gratifying to be on track with our announced timelines.”